A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Ver
A phase 3 trial of Abiraterone acetate, Prednisone in prostate cancer, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.
Overview
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer is a phase 3 interventional study registered as NCT04691804 by Jiangsu HengRui Medicine Co., Ltd., with 496 participants enrolled, started 2021-03-18 and due to reach its primary completion in 2026-12-31. Interventions recorded: Fuzuloparib , Abiraterone acetate and Prednisone, Fuzuloparib Placebo， Abiraterone acetate and Prednisone. Conditions listed: Metastatic Castration-Resistant Prostate Cancer (mCRPC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone
Shares Prednisone, Jiangsu Hengrui Pharmaceuticals, Prostate cancer.
- TrialA Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
Shares Prednisone, Abiraterone acetate, Prostate cancer.
- TrialA Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Shares Prednisone, Abiraterone acetate, Prostate cancer.
- TrialA Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
Shares Prednisone, Abiraterone acetate, Prostate cancer.
- TrialA Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
Shares Prednisone, Abiraterone acetate, Prostate cancer.
- TrialAn Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Shares Prednisone, Abiraterone acetate, Prostate cancer.
- TrialA Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer
Shares Prednisone, Abiraterone acetate, Prostate cancer.
- TrialA Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
Shares Prednisone, Jiangsu Hengrui Pharmaceuticals, Prostate cancer.